Recruiting Pulmonary Hypertension Studies in Edmonton
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
Study B7841007 is an open-label extension study to assess the long-term safety, tolerability, and efficacy of prophylaxis treatment with marstacimab in participants who did not require "Early Terminat...
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
This study will enroll male and female subjects who are 18 years of age or older with Eosinophilic Granulomatosis With Polyangiitis....
About Pulmonary Hypertension Clinical Trials in Edmonton
Pulmonary hypertension is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. It can lead to heart failure if untreated. Treatment includes vasodilators, endothelin receptor antagonists, and PDE-5 inhibitors.
There are currently 2 pulmonary hypertension clinical trials recruiting participants in Edmonton, ALBERTA. These studies are seeking a combined 290 participants. Research is being sponsored by Pfizer, NS Pharma, Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.
Pulmonary Hypertension Clinical Trials in Edmonton — FAQ
Are there pulmonary hypertension clinical trials in Edmonton?
Yes, there are 2 pulmonary hypertension clinical trials currently recruiting in Edmonton, ALBERTA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Edmonton?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Edmonton research site will contact you about next steps.
Are clinical trials in Edmonton free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Edmonton studies also compensate for your time and travel.
What pulmonary hypertension treatments are being tested?
The 2 active trials in Edmonton are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary hypertension.
Data updated March 2, 2026 from ClinicalTrials.gov